US 12,168,073 B2
Percutaneous absorption preparation comprising stabilized donepezil
Sun-Woo Jang, Seoul (KR); Chang-Yell Shin, Seoul (KR); Hae-Sun Kim, Hwaseong-Si (KR); Kwang-Ho Cha, Seoul (KR); Hyun-Jung Kim, Yongin-Si (KR); and Masaoki Goto, Osaka (JP)
Assigned to DONG-A ST CO., LTD., Seoul (KR); and KM TRANSDERM LTD., Osaka (JP)
Appl. No. 17/416,930
Filed by DONG-A ST CO., LTD., Seoul (KR); and KM TRANSDERM LTD., Osaka (JP)
PCT Filed Sep. 5, 2019, PCT No. PCT/KR2019/011483
§ 371(c)(1), (2) Date Jun. 21, 2021,
PCT Pub. No. WO2020/130287, PCT Pub. Date Jun. 25, 2020.
Claims priority of application No. 10-2018-0167289 (KR), filed on Dec. 21, 2018.
Prior Publication US 2022/0047524 A1, Feb. 17, 2022
Int. Cl. A61K 9/70 (2006.01); A61K 31/445 (2006.01); A61K 47/20 (2006.01)
CPC A61K 9/7053 (2013.01) [A61K 31/445 (2013.01); A61K 47/20 (2013.01)] 5 Claims
 
1. A percutaneous absorption preparation comprising a support layer, a drug-containing layer, and a release layer, wherein: the drug-containing layer comprises donepezil or a pharmaceutically acceptable salt thereof as an active ingredient, and a stabilizer selected from the group consisting of thiocyanate metal salt and dimethylthiourea, wherein a range of weight percentage of the stabilizer is from 0.0005% wt to 5% wt.